Recently, five studies[14,19-22] examined the presence of EGFR mutations in NSCLC by IHC using the same two rabbit mAbs and reported sensitivity ranging from 36% to 100% and specificity ranging from 94% to 99% (Table 4). This evidence concerns the gene EGFR and non-small cell lung carcinoma.